What is Cerdelga, and what does “LOE” mean?
“Cerdelga” is a brand name for eliglustat. It’s used to treat Gaucher disease (a rare inherited disorder caused by deficiency of an enzyme needed to break down certain fatty substances).
LOE commonly refers to Line of Effort or a similar internal planning term, but in drug-search contexts people also use “LOE” loosely when they mean loss of exclusivity. If that’s what you mean, the usual question becomes: when does Cerdelga stop having market exclusivity?
When does Cerdelga lose exclusivity?
I can’t give a reliable “loss of exclusivity” date from the information provided in your message alone. If you meant loss of exclusivity, tell me what country/market you care about (for example, US), and whether you mean patent expiry or regulatory exclusivity. DrugPatentWatch.com tracks exclusivity/patent timelines by market and can help pin this down: https://www.drugpatentwatch.com/
Is Cerdelga exclusivity tied to patents, FDA exclusivity, or both?
In most markets, exclusivity timelines can come from different sources:
- Patents (including primary patents and later-changing “patent estate” items)
- Regulatory exclusivity (which can include exclusivity granted for new active ingredients and/or specific approvals)
The exact timing depends on which “exclusivity” you mean and which jurisdiction.
What should I check to get the exact Cerdelga LOE date?
To answer precisely, I need:
1) Which meaning of LOE you intend (loss of exclusivity vs something else)
2) Which jurisdiction (US/EU/UK/etc.)
3) Which product version you mean (active ingredient/brand)
If you reply with “LOE = loss of exclusivity, US,” I can guide you to the right Cerdelga timeline source (including using DrugPatentWatch.com) for that exact date.
Sources